pH-Sensitive PEGylated Liposomal Silybin: Synthesis, In Vitro and In Vivo Anti-Tumor Evaluation.
4T1 breast cancer
Hydrazone bond
Silybin
Silymarin
TAT peptide
pH-sensitive liposome
Journal
Journal of pharmaceutical sciences
ISSN: 1520-6017
Titre abrégé: J Pharm Sci
Pays: United States
ID NLM: 2985195R
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
received:
20
01
2021
revised:
14
08
2021
accepted:
14
08
2021
pubmed:
22
8
2021
medline:
1
3
2022
entrez:
21
8
2021
Statut:
ppublish
Résumé
The drug delivery systems improve the efficacy of chemotherapeutics through enhanced targeting and controlled release however, biological barriers of tumor microenvironment greatly impede the penetration of nanomedicine within the tumor. We report herein the fabrication of a PEG-detachable silybin (SLB) pH-sensitive liposome decorated with TAT-peptide. For this, Acyl hydrazide-activated PEG
Identifiants
pubmed: 34418455
pii: S0022-3549(21)00416-0
doi: 10.1016/j.xphs.2021.08.015
pii:
doi:
Substances chimiques
Liposomes
0
Polyethylene Glycols
3WJQ0SDW1A
Silybin
4RKY41TBTF
Doxorubicin
80168379AG
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3919-3928Informations de copyright
Copyright © 2021 American Pharmacists Association. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that there are no conflicts of interest.